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InEngland,160000 individualswereestimated tobe chronically infectedwith
hepatitisCvirus(HCV)in2005andtheburdenofsevereHCV-relatedliverdis-








HCV prevalence to inform recent incidence. We estimated that there were
143000chronicinfectionsin2015(95%credibleinterval123000-161000),with
34% and 54% in those with recent and past injecting drug use, respectively.
Followingtheplannedscale-upofnewtreatments,chronicinfectionswerepre-
dicted to fall to 113400 (94900-132400) by the end of 2018 and to 89500
(71300-108600)bytheendof2020.NumbersdevelopingsevereHCV-related
liverdiseasewerepredictedtofallbyatleast24%from2015to2020.Thus,we
describe a coherent framework to monitor progress using routinely collected
data, which can be extended to incorporate additional data sources. Planned
treatmentscale-upislikelytoachieve2020WHOtargetsforHCVmorbidity,but
substantial effortswill be required to ensure thatHCV testing andpatient en-
gagementaresufficientlyhigh.
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1  | INTRODUC TION
HepatitisCvirus(HCV)isablood-borneinfectionthatcausespro-
gressive fibrosis of the liver and can lead to cirrhosis andhepato-








the next decade.6However,new treatmentscanclear thevirus in
themajorityof those infected, including thosewith advanceddis-
ease.7,8Suchisthecurrentoptimismthatmanycountriesareinthe
process of setting timelines for eliminatingHCVas amajor public
health threat by 2030or before,9 as set out by theWorldHealth

















typicallymake inferences using data on disease endpoints, which
aremodelledviaback-calculationorusedtocalibratemathematical
models.15–17




collected infrequently and information on ex-PWID is limited.3,21 
Conversely,theback-calculationmodelcanbeusedtoreconstruct
the historical pattern ofHCV infections, on the basis of the time
between infection and disease endpoints. However, estimates of
recentincidence,andthereforeoverallprevalence,aremoreuncer-




of the PWID population and on the proportion of HCV-infected
PWIDcanbeincorporated,tobetterinformrecentHCVincidence
andestimatedprevalence.
2  | MATERIAL S AND METHODS























The yearly Unlinked Anonymous Monitoring (UAM) survey
providesdataonHCVantibodyprevalence inPWID.5,25PWIDat-
tendinglowthreshold(needle-exchange)ortreatmentservicesare







Research commissioned by the former National Treatment
Agency(NTA)estimatedthatinthefinancialyear2010/11,93401
peopleaged15-64hadinjectedopiatesorcrackcocaineinthelast
year, henceforth referred to as the NTA estimates.28 Of principal
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saleswere used to derive numbers treatedwith interferon-based
therapy from2006 to2011.6Patternsof repeat testing indicative
oftreatmentfromsentinelsurveillance30wereusedtopredicttreat-
mentnumbers from2012 to2015.From2016onwards, numbers
treatedwithnewdirect-actingantiviralswereprovideddirectlyfrom











definedonthebasisofamodifiedHAIscore,2 mild chronic,moderate 








In addition to the risk group/disease state structuredescribed
above, the infected population is further compartmentalized into



























































Non-HCV-related death (all states/risk groups)
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viral response (SVR) states, the latter being the result of success-



























treated, and the SVR rate. Probabilities of treatment, conditional
on having been diagnosed, are assumed equal across age groups,
riskgroupsanddisease stages (theseassumptionsareexplored in
sensitivity analysis). Probabilities of SVR under interferon-based
therapiesareassignedfixedvaluesbasedonpublishedestimates,8 
andnewtherapiesassignedafixed90%intention-to-treatprobabil-
ityofSVR.The infection ratevia routesother than injectingdrug
use, annual probabilities ofmortality and post-SVR risk ratios for
developingESLD/HCCareassumedtobeknown(seeAppendixS4).

















3.1 | Parameter estimates and model fit
Figure2showstheestimatednumberofpeopleinitiatinginjecting
































































Base model Base model 95% CrI
All HES data HES data 2004-2010












with19%of those injecting foroneyear testingpositive forHCV
antibodiesintheUAMdata,risingtoover40%inthoseinjectingfor
8yearsormore.Figure3showsobservedHCVantibodyprevalence
in theUAMdata and that predicted under themodel. Themodel
capturestherelationshipbetweeninjectingdurationandproportion
infectedovertimewell,althoughcredibleintervalsareverynarrow




prior values, although posterior probabilities of progression from
cirrhosistoESLDwerehigherthanthosespecifiedbytheprior, in
















foradiseasewith long incubation timeand time-invariantdisease
progression.When restrictinganalysis to the2011-2016period, a
betterfitwasobtainedtothesedata,butthemodelproducedover-
estimates for the 2004-2010 period. Conversely, modelling the
2004-2010dataaloneresultedinunder-estimatesfor2011-2016.
3.2 | Prevalence estimates and predictions
Weestimated that thenumberofPWIDaged15-64 in2011was

















































































































































Mild to moderate Moderate to cirrhosis
Cirrhosis to ESLD Cirrhosis to HCC
Prior distribution Base model posterior






















































































































































ESLD, 1920-1939 ESLD, 1940-1959 ESLD, 1960-1979 ESLD, 1980-1999
HCC, 1920-1939 HCC, 1940-1959 HCC, 1960-1999
Observed data, 2004-2010 Observed data, 2011-2016
Base model estimate Estimate with all HES data
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TABLE  1 Estimatedriskgroupsizesandchronicinfections,2005and2015
Age group Group size Chronic infection % infected
2005
PWID
0-29 64900(56100-74100) 18200(15500-20800) 28%(27-29%)
30-39 56800(42600-73800) 24000(17300-32300) 42%(40-44%)
40-49 30600(19000-47000) 16700(10000-26400) 55%(52-56%)
50-59 9500(4850-17000) 5900(2900-10800) 62%(59-64%)
60+ 2000(880-4350) 1350(590-2950) 67%(64-70%)
Total 164200(123600-213300) 66200(46400-92400) 40%(37-44%)
Permanentlyceasedinjecting
0-29 68600(56500-84800) 8500(6100-11300) 12%(11-14%)
30-39 134400(108300-164300) 27300(20400-34500) 20%(19-21%)
40-49 141700(112500-176300) 35200(26700-43100) 25%(23-26%)
50-59 80200(64100-101800) 19300(15100-24100) 24%(21-26%)
60+ 46900(37500-56800) 8700(7000-11200) 19%(15-22%)
Total 474700(380200-568700) 99400(75800-119400) 21%(20-22%)
Neverinjecteddrugsa
SouthAsianethnicity 2641000 8500 0.32%
White/otherethnicity 47500000 10500 0.022%
Allriskgroups
Total 53910000 179000(161000-198000) 0.35%(0.32-0.39%)
2015
CurrentPWID
0-29 39000(30300-51500) 10800(8600-14600) 28%(26-30%)
30-39 36100(25300-47900) 13700(9300-18600) 38%(36-39%)
40-49 29000(17100-45300) 13600(7700-22100) 47%(45-50%)
50-59 13600(6500-25300) 7500(3500-14600) 56%(54-59%)
60+ 3750(1450-8500) 2350(870-5400) 61%(59-64%)
Total 121100(83300-167800) 48100(30500-71200) 40%(36-44%)
Permanentlyceasedinjecting
0-29 37100(28800-47900) 4500(3100-6300) 12%(11-14%)
30-39 92600(75200-114100) 13000(9900-16600) 14%(13-15%)
40-49 151000(122800-180500) 25100(20000-30900) 17%(16-18%)
50-59 135600(109500-168900) 24700(19600-31200) 18%(17-20%)
60+ 92700(76200-117400) 13100(9700-17400) 14%(12-17%)
Total 513200(415200-598700) 80900(64400-95700) 16%(15-17%)
Neverinjecteddrugsa
SouthAsianethnicity 3331000 8300 0.25%
White/otherethnicity 49950000 8200 0.016%
Allriskgroups
















In total, we estimated that there were 143,000 (95% CrI:





We assumed that numbers treated with direct-acting antivi-
ralswill increase fromaround11500per year in2017 to15000




CrI: 71300-108600) by the end of 2020, reductions of around
20%and37%, respectively, compared to2015.Theproportionof





















berofpeoplewithchronic infection,given the riskof infection in
PWIDandcessationrate.Ifthisinformationisomitted,thenumber
ofchronicinfectionsin2015wasestimatedtobe218200(175500-
252800). This is largely driven by the data on ESLD:whenmod-
ellingdataonHCCalone,estimateswerecomparable to thebase







related severe liver disease; if the true incidence is higher, this
pushesprevalenceupwards.The impact is smaller ifHCCalone is





































































absence of treatment scale-up.6 The impact of DAAs on severe
HCV-relatedliverdiseasewillbefurtherexploredasmoredetailed
treatmentandoutcomesdata,inparticularforthosewithcirrhosis,






numberdiagnoseddue tounder-reporting, there isaconcern that
thenumberofdiagnosedindividualsavailabletobetreatedmaynot
keeppacewithplannedincreasesintreatment.
































proportions and levels of risk on overall prevalencewasminimal,
withonlytheestimatednumberofex-PWIDchangingmaterially.
We chose to base inferences onmore recent HES data (2011-
2016),whichresultedinhigherestimatesofHCV-relatedESLD/HCC
than thoseobserved for the2004-2010period.The rapid increase
inobservednumbersofESLD/HCCaround2010-2011maybeex-
plainedbychangesinHCVreporting,whichmayhaveimprovedgen-
















Previous multi-parameter evidence synthesis (MPES) models
providedanestimateof160000chronicinfectionsin2005,which






estimated that in the UK there were 189000 chronic infections























infection and disease progression within a statistical model. This
general framework could be applied toother countries and incor-
poratedifferentdatasourcesondiseaseendpoints,serosurveillance
and injecting drug use as available, with the aim of constructing
a pictureof theHCVepidemic that is consistentwith all relevant
sourcesofinformation.
In conclusion,ouranalytic approachprovides the template for













Viral Hepatitis, whose members provided valuable input for this
work,andDrPaulBirrellforhisinsightsonBayesianmodelling.We
thank all the participants of theUnlinkedAnonymousMonitoring
surveyonpeoplewho injectdrugswhogive their timetoprovide
thisinvaluableresource.
ORCID
Ross J. Harris  https://orcid.org/0000-0003-3190-7281 
Mary Ramsay  https://orcid.org/0000-0002-7156-7640 
Peter Vickerman  https://orcid.org/0000-0002-8291-5890 
Matthew Hickman  https://orcid.org/0000-0001-9864-459X     
R E FE R E N C E S
 1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natu-
ral history of HCV infection. Nat Rev Gastroenterol Hepatol. 
2013;10(9):553-562.
 2. SweetingMJ, De Angelis D, Neal KR, et al. Estimated progres-
sion rates in threeUnitedKingdomhepatitisCcohortsdiffered









 5. SweetingMJ, Hope VD, HickmanM, et al. Hepatitis C infection
among injecting drug users in England and Wales (1992-2006):
thereandbackagain?Am J Epidemiol.2009;170(3):352-360.
 6. HarrisRJ,ThomasB,Griffiths J,etal. Increaseduptakeandnew
therapiesareneededtoavertrisinghepatitisC-relatedendstage
liverdisease inEngland:modelling thepredicted impactof treat-
mentunderdifferentscenarios.J Hepatol.2014;61:530-537.
 7. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbu-






 9. NHS England. NHS England sets out plans to be first in the
world to eliminate Hepatitis C. 2018. https://www.england.nhs.
uk/2018/01/hepatitis-c-2/.








13. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepati-
tis C virus infection in the United States, National Health and
Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 
2014;160(5):293-300.
14. Prevost TC, Presanis AM, Taylor A,GoldbergDJ,Hutchinson SJ,
De Angelis D. Estimating the number of people with hepatitis
C virus who have ever injected drugs and have yet to be diag-
nosed: An evidence synthesis approach for Scotland. Addiction. 
2015;110(8):1287-1300.




hepatitis C virus (HCV)-infected persons in the United States: A
multiplecohortmodelofHCVprevalenceanddiseaseprogression.
Gastroenterology.2010;138(2):513-521.
17. Deuffic-Burban S,Deltenre P, ButiM, et al. Predicted effects of






19. Harris RJ, RamsayM, Hope VD, et al. Hepatitis C prevalence in
Englandremainslowandvariesbyethnicity:anupdatedevidence
synthesis.Eur J Public Health.2012;22(2):187-192.
20. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG,
RamsayME. The burden of hepatitis C in England. J Viral Hepat. 
2007;14(8):570-576.
21. SweetingMJ,DeAngelisD, AdesA,HickmanM. Estimating the
prevalenceofex-injectingdruguseinthepopulation.Stat Methods 
Med Res.2009;18(4):381-395.




compensatedcirrhosis typeC:a retrospective follow-upstudyof
384patients.Gastroenterology.1997;112(2):463-472.
24. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular car-





26. Ades AE, Nokes DJ. Modeling age- and time-specific inci-





28. HayG,dosSantosAR,WorsleyJ.Estimates of the prevalence of opi-






and effect of opiate substitution treatment. BMJ. 2010;341: 
c3172.
30. Lattimore S, IrvingW,Collins S, et al. Using surveillance data to
determinetreatmentratesandoutcomesforpatientswithchronic
hepatitisCvirusinfection.Hepatology.2014;59(4):1343-1350.
31. Pearlman BL, Traub N. Sustained virologic response to antiviral
therapyforchronichepatitisCvirusinfection:acureandsomuch
more. Clin Infect Dis.2011;52(7):889-900.
32. SingalAG,VolkML,JensenD,DiBisceglieAM,SchoenfeldPS.A
sustained viral response is associated with reduced liver-related






34. Gaudy-Graffin C, Lesage G, Kousignian I, et al. Use of an anti-




36. MartinNK,VickermanP,Grebely J,etal.HepatitisCvirus treat-














Additional supporting information may be found online in the
SupportingInformationsectionattheendofthearticle.
How to cite this article:HarrisRJ,HarrisHE,MandalS,etal.
MonitoringthehepatitisCepidemicinEnglandand
evaluatinginterventionscale-upusingroutinelycollected
data. J Viral Hepat. 2019;00:1–12. https://doi.org/10.1111/
jvh.13063
